IM
KYMR icon

Islet Management’s Kymera Therapeutics KYMR Stock Holding History

Islet Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,600
Closed -$1.1M – 246
2021
Q2 		$1.1M Buy
+22,600
New +$981K 0.03% 155

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Islet Management's KYMR Position: Q3 2021 in Review

Islet Management sold out of Kymera Therapeutics (KYMR) in Q3 2021, closing a stake of 25,000 shares — an estimated $1.21M sold.

Islet Management first reported a position in KYMR in Q2 2021 and held it in 1 quarter. The position peaked at $1.21M in Q2 2021. 115 funds tracked by Wall St. Rank hold KYMR as of Q3 2021.

  • Islet Management reported no remaining Kymera Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Islet Management sold 25,000 Kymera Therapeutics shares in Q3 2021, an estimated $1.21M.
  • Islet Management first reported a position in Kymera Therapeutics in Q2 2021 and held it in 1 quarter.
  • Islet Management's Kymera Therapeutics position peaked at $1.21M in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2021.

Based on Islet Management's 13F filing for Q3 2021, filed 15 Nov 2021.